Skip to Content

Fenofibrate Dosage

Medically reviewed by Drugs.com. Last updated on Mar 18, 2019.

Applies to the following strengths: 48 mg; 145 mg; 54 mg; 160 mg; 67 mg; micronized 200 mg; 134 mg; 40 mg; 120 mg; 43 mg; 130 mg; 30 mg; 90 mg; 50 mg; 150 mg

Usual Adult Dose for Hyperlipidemia

Multiple products available to include micronized capsules, capsules, and tablets: dosing provided for formulations listed below:

1 capsule or tablet orally once a day
-Maximum dose: 1 tablet or capsule orally once a day

-Antara (micronized capsules): 90 mg
-Antara (micronized capsules): 130 mg
-Lipofen (capsules): 150 mg
-Fenoglide (tablet): 120 mg
-Tricor (tablet): 145 mg
-Triglide (tablet): 160 mg

Comments:
-Therapy should be withdrawn if inadequate response after 2 months of treatment.
-This drug is intended to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein (HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia.

Uses: As an adjunct therapy to diet for the treatment of primary hypercholesterolemia and mixed dyslipidemia.

Usual Adult Dose for Hyperlipoproteinemia Type IIa (Elevated LDL)

Multiple products available to include micronized capsules, capsules, and tablets: dosing provided for formulations listed below:

1 capsule or tablet orally once a day
-Maximum dose: 1 tablet or capsule orally once a day

-Antara (micronized capsules): 90 mg
-Antara (micronized capsules): 130 mg
-Lipofen (capsules): 150 mg
-Fenoglide (tablet): 120 mg
-Tricor (tablet): 145 mg
-Triglide (tablet): 160 mg

Comments:
-Therapy should be withdrawn if inadequate response after 2 months of treatment.
-This drug is intended to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein (HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia.

Uses: As an adjunct therapy to diet for the treatment of primary hypercholesterolemia and mixed dyslipidemia.

Usual Adult Dose for Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL)

Multiple products available to include micronized capsules, capsules, and tablets: dosing provided for formulations listed below:

1 capsule or tablet orally once a day
-Maximum dose: 1 tablet or capsule orally once a day

-Antara (micronized capsules): 90 mg
-Antara (micronized capsules): 130 mg
-Lipofen (capsules): 150 mg
-Fenoglide (tablet): 120 mg
-Tricor (tablet): 145 mg
-Triglide (tablet): 160 mg

Comments:
-Therapy should be withdrawn if inadequate response after 2 months of treatment.
-This drug is intended to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein (HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia.

Uses: As an adjunct therapy to diet for the treatment of primary hypercholesterolemia and mixed dyslipidemia.

Usual Adult Dose for Dyslipidemia

Multiple products available to include micronized capsules, capsules, and tablets: dosing provided for formulations listed below:

1 capsule or tablet orally once a day
-Maximum dose: 1 tablet or capsule orally once a day

-Antara (micronized capsules): 90 mg
-Antara (micronized capsules): 130 mg
-Lipofen (capsules): 150 mg
-Fenoglide (tablet): 120 mg
-Tricor (tablet): 145 mg
-Triglide (tablet): 160 mg

Comments:
-Therapy should be withdrawn if inadequate response after 2 months of treatment.
-This drug is intended to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein (HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia.

Uses: As an adjunct therapy to diet for the treatment of primary hypercholesterolemia and mixed dyslipidemia.

Usual Adult Dose for Hyperlipoproteinemia Type IV (Elevated VLDL)

Dosing is product specific; available as micronized capsules, capsules, and tablets:

MICRONIZED CAPSULES:
-Antara: Initial dose: 30 to 90 mg orally once a day; maximum dose: 90 mg/day
-Antara: Initial dose: 43 to 130 mg orally once a day; maximum dose: 130 mg/day
-Fenofibrate: Initial dose: 67 to 200 mg orally once a day; maximum dose 200 mg/day
CAPSULES:
-Lipofen (capsules): Initial dose: 50 to 150 mg orally once a day; maximum dose: 150 mg/day
TABLETS:
-Fenoglide (tablets): Initial dose: 40 to 120 mg orally once a day; maximum dose: 120 mg/day
-Tricor (tablets): Initial dose: 48 to 145 mg orally once a day: maximum dose 145 mg/day
-Fenofibrate (tablets): Initial dose: 54 to 160 mg orally once a day; maximum dose: 160 mg/day
-Triglide (tablets): 160 mg orally once a day; maximum dose: 160 mg/day

TITRATION: Individualize dose according to response and adjust as necessary following repeat lipid determinations at 4- to 8-week intervals; if lipid levels fall significantly, dose reduction should be considered.

Comments:
-Doses should be swallowed whole, tablets should not be split, capsules should not be opened.
-Therapy should be withdrawn if inadequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia.

Usual Adult Dose for Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL)

Dosing is product specific; available as micronized capsules, capsules, and tablets:

MICRONIZED CAPSULES:
-Antara: Initial dose: 30 to 90 mg orally once a day; maximum dose: 90 mg/day
-Antara: Initial dose: 43 to 130 mg orally once a day; maximum dose: 130 mg/day
-Fenofibrate: Initial dose: 67 to 200 mg orally once a day; maximum dose 200 mg/day
CAPSULES:
-Lipofen (capsules): Initial dose: 50 to 150 mg orally once a day; maximum dose: 150 mg/day
TABLETS:
-Fenoglide (tablets): Initial dose: 40 to 120 mg orally once a day; maximum dose: 120 mg/day
-Tricor (tablets): Initial dose: 48 to 145 mg orally once a day: maximum dose 145 mg/day
-Fenofibrate (tablets): Initial dose: 54 to 160 mg orally once a day; maximum dose: 160 mg/day
-Triglide (tablets): 160 mg orally once a day; maximum dose: 160 mg/day

TITRATION: Individualize dose according to response and adjust as necessary following repeat lipid determinations at 4- to 8-week intervals; if lipid levels fall significantly, dose reduction should be considered.

Comments:
-Doses should be swallowed whole, tablets should not be split, capsules should not be opened.
-Therapy should be withdrawn if inadequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia.

Usual Adult Dose for Hypertriglyceridemia

Dosing is product specific; available as micronized capsules, capsules, and tablets:

MICRONIZED CAPSULES:
-Antara: Initial dose: 30 to 90 mg orally once a day; maximum dose: 90 mg/day
-Antara: Initial dose: 43 to 130 mg orally once a day; maximum dose: 130 mg/day
-Fenofibrate: Initial dose: 67 to 200 mg orally once a day; maximum dose 200 mg/day
CAPSULES:
-Lipofen (capsules): Initial dose: 50 to 150 mg orally once a day; maximum dose: 150 mg/day
TABLETS:
-Fenoglide (tablets): Initial dose: 40 to 120 mg orally once a day; maximum dose: 120 mg/day
-Tricor (tablets): Initial dose: 48 to 145 mg orally once a day: maximum dose 145 mg/day
-Fenofibrate (tablets): Initial dose: 54 to 160 mg orally once a day; maximum dose: 160 mg/day
-Triglide (tablets): 160 mg orally once a day; maximum dose: 160 mg/day

TITRATION: Individualize dose according to response and adjust as necessary following repeat lipid determinations at 4- to 8-week intervals; if lipid levels fall significantly, dose reduction should be considered.

Comments:
-Doses should be swallowed whole, tablets should not be split, capsules should not be opened.
-Therapy should be withdrawn if inadequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia.

Usual Geriatric Dose for Hyperlipidemia

Dose selection should be based on renal function

-Fenofibrate micronized capsules: Initial dose: 67 mg orally once a day; titrate as indicated; maximum dose 200 mg/day
-All other fenofibrate products: See Adult Dosage

Comments:
-Consider renal function monitoring in elderly patients.
-Fenofibric acid exposure is not influenced by age, but due to substantial renal excretion, it is affected by renal function.

Usual Geriatric Dose for Hypertriglyceridemia

Dose selection should be based on renal function

-Fenofibrate micronized capsules: Initial dose: 67 mg orally once a day; titrate as indicated; maximum dose 200 mg/day
-All other fenofibrate products: See Adult Dosage

Comments:
-Consider renal function monitoring in elderly patients.
-Fenofibric acid exposure is not influenced by age, but due to substantial renal excretion, it is affected by renal function.

Usual Geriatric Dose for Dyslipidemia

Dose selection should be based on renal function

-Fenofibrate micronized capsules: Initial dose: 67 mg orally once a day; titrate as indicated; maximum dose 200 mg/day
-All other fenofibrate products: See Adult Dosage

Comments:
-Consider renal function monitoring in elderly patients.
-Fenofibric acid exposure is not influenced by age, but due to substantial renal excretion, it is affected by renal function.

Renal Dose Adjustments

Mild to moderate renal dysfunction: Initiate at lower doses and increase only after evaluating the effects of therapy on renal function and lipid levels:
-Antara (micronized capsules): Initial dose: 30 mg orally once a day
-Antara (micronized capsules): Initial dose: 43 mg orally once a day
-Fenofibrate (micronized capsules): Initial dose: 67 mg orally once a day
-Lipofen (capsules): Initial dose: 50 mg orally once a day
-Fenoglide (tablets): Initial dose: 40 mg orally once a day
-Tricor (tablets): Initial dose: 48 mg orally once a day
-Triglide (tablets): Avoid use

Severe renal impairment: Contraindicated

Liver Dose Adjustments

Active liver disease: Contraindicated

Discontinue therapy if enzyme levels persist at 3 times the upper limit of normal

Dose Adjustments

Elderly: Due to the higher incidence of renal impairment in this patient population, dose selection should be based on renal function; monitor renal function during therapy

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to fenofibrate, fenofibric acid, or any product excipients
-Active liver disease including primary biliary cirrhosis and unexplained persistent liver function abnormalities
-Severe renal impairment, including dialysis
-Preexisting gallbladder disease
-Lactation

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Contraindicated

Other Comments

Administration advice:
-May be taken with food to increase absorption
-Swallow capsules and tablets whole; do not break, open, crush, dissolve, or chew

Concomitant use with bile acid binding resin:
-Take at least 1 hour before or 4 to 6 hours after bile acid binding resin

Storage requirements:
-Protect from light and moisture
-Triglide(R): Dispense in original bottle

General:
-Prior to initiating therapy, diseases contributing to hyperlipidemia should be assessed and adequately treated; medications associated with elevated triglycerides should be evaluated.
-In patients with type 2 diabetes showing fasting chylomicronemia, improving glycemic control may reduce fasting triglycerides and eliminate need for drug treatment.
-Initial treatment for dyslipidemia should be dietary specific targeted at the type of lipoprotein abnormality.
-This drug has not been shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.
-Markedly elevated levels of serum triglycerides (e.g. greater than 2000 mg/dL) may increase the risk of developing pancreatitis; the effect of this drug on reducing this risk has not been adequately studied.

Monitoring:
-Hematologic: Monitor RBC and WBC counts periodically during the first 12 months of therapy
-Hepatic: Measure liver function at baseline and periodically thought-out therapy
-Metabolic: Periodically measure lipid levels and adjust dose accordingly
-Renal: Monitor renal function in patients with renal impairment or those at risk for renal insufficiency (e.g., elderly)
-More frequent PT/INR monitoring until PT/INR stabilizes

Patient advice:
-Patients should be instructed to follow a lipid-modifying diet during therapy.
-Patients should be instructed to immediately report any muscle pain, tenderness, or weakness, onset of abdominal pain, or any other new symptoms.
-Patients should be instructed to notify their healthcare provider of all medications, supplements, and herbal preparations they are taking.
-Patients should be instructed to talk to their health care provider if they are pregnant, planning to become pregnant, or breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide